{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:27:08Z","timestamp":1775820428694,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013072","name":"Major Science and Technology Project of Hainan Province","doi-asserted-by":"publisher","award":["ZDYF2024SHFZ064"],"award-info":[{"award-number":["ZDYF2024SHFZ064"]}],"id":[{"id":"10.13039\/501100013072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hainan Province","doi-asserted-by":"publisher","award":["825CXTD610"],"award-info":[{"award-number":["825CXTD610"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07901-z","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:34:19Z","timestamp":1772627659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Chao","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaojie","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinzheng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongxu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindong Ding","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"2","key":"7901_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","volume":"79","author":"MH Le","year":"2023","unstructured":"Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, Lee K, Stave CD, Henry L, Barnett SD, et al. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79(2):287\u201395.","journal-title":"J Hepatol"},{"key":"7901_CR2","doi-asserted-by":"crossref","unstructured":"Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. MAFLD and risk of CKD. Metabolism: clinical and experimental. 2021;115:154433.","DOI":"10.1016\/j.metabol.2020.154433"},{"issue":"6","key":"7901_CR3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology (Baltimore MD). 2023;78(6):1966\u201386.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"1","key":"7901_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156\u201362.","journal-title":"Gut"},{"issue":"Suppl","key":"7901_CR5","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32\u201350.","journal-title":"Clin Mol Hepatol"},{"key":"7901_CR6","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2147\/DMSO.S237700","volume":"13","author":"YJ Lee","year":"2020","unstructured":"Lee YJ, Wang CP, Hung WC, Tang WH, Chang YH, Hu DW, Lu YC, Yu TH, Wu CC, Chung FM, et al. Common and unique factors and the bidirectional relationship between chronic kidney disease and nonalcoholic fatty liver in type 2 diabetes patients. Diabetes metabolic syndrome obesity: targets therapy. 2020;13:1203\u201314.","journal-title":"Diabetes metabolic syndrome obesity: targets therapy"},{"issue":"5","key":"7901_CR7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jhep.2010.11.007","volume":"54","author":"G Targher","year":"2011","unstructured":"Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol. 2011;54(5):1020\u20139.","journal-title":"J Hepatol"},{"key":"7901_CR8","doi-asserted-by":"crossref","unstructured":"Notarnicola M, Osella AR, Caruso MG, Pesole PL, Lippolis A, Tutino V, Bonfiglio C, De Nunzio V, Scavo MP, Mirizzi A, et al. Nonalcoholic fatty liver disease: focus on new biomarkers and lifestyle interventions. Int J Mol Sci. 2021;22(8).","DOI":"10.3390\/ijms22083899"},{"issue":"11","key":"7901_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","volume":"20","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Lifestyle interventions in nonalcoholic fatty liver disease. Nat reviews Gastroenterol Hepatol. 2023;20(11):708\u201322.","journal-title":"Nat reviews Gastroenterol Hepatol"},{"key":"7901_CR10","doi-asserted-by":"crossref","unstructured":"Bern\u00e1 G, Romero-Gomez M. The role of nutrition in non-alcoholic fatty liver disease: pathophysiology and management. Liver International. 2020;40:102\u20138:Suppl 1.","DOI":"10.1111\/liv.14360"},{"issue":"7","key":"7901_CR11","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1053\/j.gastro.2020.01.049","volume":"158","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Cl\u00e9ment K. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? Gastroenterology. 2020;158(7):1881\u201398.","journal-title":"Gastroenterology"},{"issue":"4","key":"7901_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.dsx.2018.03.016","volume":"12","author":"HM Al-Dayyat","year":"2018","unstructured":"Al-Dayyat HM, Rayyan YM, Tayyem RF. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors. Diabetes metabolic syndrome. 2018;12(4):569\u201375.","journal-title":"Diabetes metabolic syndrome"},{"key":"7901_CR13","doi-asserted-by":"crossref","unstructured":"Yuan S, Chen J, Li X, Fan R, Arsenault B, Gill D, Giovannucci EL, Zheng JS, Larsson SC. Lifestyle and metabolic factors for nonalcoholic fatty liver disease: mendelian randomization study. Eur J Epidemiol 2022, 37(7):723\u201333.","DOI":"10.1007\/s10654-022-00868-3"},{"issue":"7","key":"7901_CR14","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851\u201364.","journal-title":"Gastroenterology"},{"issue":"2","key":"7901_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jhep.2013.03.035","volume":"59","author":"CW Kim","year":"2013","unstructured":"Kim CW, Yun KE, Jung HS, Chang Y, Choi ES, Kwon MJ, Lee EH, Woo EJ, Kim NH, Shin H, et al. Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses. J Hepatol. 2013;59(2):351\u20137.","journal-title":"J Hepatol"},{"key":"7901_CR16","doi-asserted-by":"crossref","unstructured":"Um YJ, Chang Y, Jung HS, Cho IY, Shin JH, Shin H, Wild SH, Byrne CD, Ryu S. Decrease in sleep duration and poor sleep quality over time is associated with an increased risk of incident non-alcoholic fatty liver disease. J personalized Med 2022, 12(1).","DOI":"10.3390\/jpm12010092"},{"key":"7901_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.sleep.2019.02.012","volume":"57","author":"JH Kim","year":"2019","unstructured":"Kim JH, Jung DH, Kwon YJ, Lee JI, Shim JY. The impact of the sleep duration on NAFLD score in Korean middle-aged adults: a community-based cohort study. Sleep Med. 2019;57:144\u201350.","journal-title":"Sleep Med"},{"key":"7901_CR18","doi-asserted-by":"crossref","unstructured":"Miao Y, Kong X, Zhao B, Fang F, Chai J, Huang J. Loneliness and social isolation with risk of incident non-alcoholic fatty liver disease, UK Biobank 2006 to 2022. Health Data Science. 2025;5:0220.","DOI":"10.34133\/hds.0220"},{"issue":"1","key":"7901_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12933-024-02347-3","volume":"23","author":"N Zhang","year":"2024","unstructured":"Zhang N, Liu X, Wang L, Zhang Y, Xiang Y, Cai J, Xu H, Xiao X, Zhao X. Lifestyle factors and their relative contributions to longitudinal progression of cardio-renal-metabolic multimorbidity: a prospective cohort study. Cardiovasc Diabetol. 2024;23(1):265.","journal-title":"Cardiovasc Diabetol"},{"key":"7901_CR20","doi-asserted-by":"crossref","unstructured":"Huang Y, Xu J, Yang Y, Wan T, Wang H, Li X. Association between Lifestyle modification and all-cause, cardiovascular, and premature mortality in individuals with non-alcoholic fatty liver disease. Nutrients. 2024;16(13).","DOI":"10.3390\/nu16132063"},{"issue":"10","key":"7901_CR21","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.2337\/dc24-0864","volume":"47","author":"ZG Huang","year":"2024","unstructured":"Huang ZG, Gao JW, Chen ZT, Zhang HF, You S, Xiong ZC, Wu YB, Gao QY, Wang JF, Chen YX, et al. Comprehensive multiple risk factor control in type 2 diabetes to mitigate heart failure risk: insights from a prospective cohort study. Diabetes Care. 2024;47(10):1818\u201325.","journal-title":"Diabetes Care"},{"key":"7901_CR22","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical. Practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"7901_CR23","first-page":"n604","volume":"373","author":"YB Zhang","year":"2021","unstructured":"Zhang YB, Chen C, Pan XF, Guo J, Li Y, Franco OH, Liu G, Pan A. Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: two prospective cohort studies. BMJ (Clinical Res ed). 2021;373:n604.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"8","key":"7901_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamacardio.2018.1717","volume":"3","author":"MA Said","year":"2018","unstructured":"Said MA, Verweij N, van der Harst P. Associations of combined genetic and lifestyle risks with incident cardiovascular disease and diabetes in the UK biobank study. JAMA Cardiol. 2018;3(8):693\u2013702.","journal-title":"JAMA Cardiol"},{"key":"7901_CR25","doi-asserted-by":"crossref","unstructured":"Yin J, Jin X, Shan Z, Li S, Huang H, Li P, et al. Relationship of sleep duration with all-cause mortality and cardiovascular events: a systematic review and dose-response meta-analysis of prospective cohort studies. Journal of the American Heart Association. 2017;6(9).","DOI":"10.1161\/JAHA.117.005947"},{"key":"7901_CR26","doi-asserted-by":"crossref","unstructured":"Gr\u00f8ntved A, Hu FB. Television viewing and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a meta-analysis. JAMA. 2011;305(23):2448-2455.","DOI":"10.1001\/jama.2011.812"},{"issue":"9","key":"7901_CR27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41588-022-01165-1","volume":"54","author":"Z Wang","year":"2022","unstructured":"Wang Z, Emmerich A, Pillon NJ, Moore T, Hemerich D, Cornelis MC, Mazzaferro E, Broos S, Ahluwalia TS, Bartz TM, et al. Genome-wide association analyses of physical activity and sedentary behavior provide insights into underlying mechanisms and roles in disease prevention. Nat Genet. 2022;54(9):1332\u201344.","journal-title":"Nat Genet"},{"issue":"4","key":"7901_CR28","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1016\/S2468-2667(20)30291-7","volume":"6","author":"RW Smith","year":"2021","unstructured":"Smith RW, Barnes I, Green J, Reeves GK, Beral V, Floud S. Social isolation and risk of heart disease and stroke: analysis of two large UK prospective studies. Lancet Public health. 2021;6(4):e232\u20139.","journal-title":"Lancet Public health"},{"issue":"10","key":"7901_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","volume":"21","author":"G Musso","year":"2015","unstructured":"Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med. 2015;21(10):645\u201362.","journal-title":"Trends Mol Med"},{"issue":"6","key":"7901_CR30","first-page":"458","volume":"8","author":"H Liu","year":"2022","unstructured":"Liu H, Zhang C, Xiong J. Pathological Connections between Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease. Kidney Dis (Basel Switzerland). 2022;8(6):458\u201365.","journal-title":"Kidney Dis (Basel Switzerland)"},{"issue":"10","key":"7901_CR31","doi-asserted-by":"publisher","first-page":"102873","DOI":"10.1016\/j.dsx.2023.102873","volume":"17","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang T, Liu Y, Bai S, Jiang J, Zhou H, Luan J, Cao L, Lv Y, Zhang Q, et al. Adherence to healthy lifestyle was associated with an attenuation of the risk of chronic kidney disease from metabolic dysfunction-associated fatty liver disease: Results from two prospective cohorts. Diabetes metabolic syndrome. 2023;17(10):102873.","journal-title":"Diabetes metabolic syndrome"},{"issue":"1","key":"7901_CR32","doi-asserted-by":"publisher","first-page":"12645","DOI":"10.1038\/s41598-024-63386-0","volume":"14","author":"C Cen","year":"2024","unstructured":"Cen C, Fan Z, Ding X, Tu X, Liu Y. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study. Sci Rep. 2024;14(1):12645.","journal-title":"Sci Rep"},{"key":"7901_CR33","doi-asserted-by":"crossref","unstructured":"Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol 2022, 28(39):5691\u2013706.","DOI":"10.3748\/wjg.v28.i39.5691"},{"issue":"3","key":"7901_CR34","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/hbsn-22-421","volume":"12","author":"DQ Sun","year":"2023","unstructured":"Sun DQ, Targher G, Byrne CD, Wheeler DC, Wong VW, Fan JG, Tilg H, Yuan WJ, Wanner C, Gao X, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg Nutr. 2023;12(3):386\u2013403.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"7901_CR35","doi-asserted-by":"crossref","unstructured":"Lange NF, Radu P, Dufour JF. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention. Journal of Hepatology. 2021;75(5):1217-1227.","DOI":"10.1016\/j.jhep.2021.07.025"},{"key":"7901_CR36","doi-asserted-by":"crossref","unstructured":"He P, Zhang Y, Ye Z, Li H, Liu M, Zhou C, et al. A healthy lifestyle, Life's Essential 8 scores and new-onset severe NAFLD: a prospective analysis in UK Biobank. Metabolism: Clinical and Experimental. 2023;146:155643.","DOI":"10.1016\/j.metabol.2023.155643"},{"key":"7901_CR37","doi-asserted-by":"crossref","unstructured":"Ahmed S, Hasan MM, Khan H, Mahmood ZA, Patel S. The mechanistic insight of polyphenols in calcium oxalate urolithiasis mitigation. Biomedicine & Pharmacotherapy. 2018;106:1292-1299.","DOI":"10.1016\/j.biopha.2018.07.080"},{"key":"7901_CR38","doi-asserted-by":"publisher","first-page":"111658","DOI":"10.1016\/j.ejmech.2019.111658","volume":"183","author":"S Ahmed","year":"2019","unstructured":"Ahmed S, Khan H, Mirzaei H. Mechanics insights of curcumin in myocardial ischemia: Where are we standing? Eur J Med Chem. 2019;183:111658.","journal-title":"Eur J Med Chem"},{"key":"7901_CR39","doi-asserted-by":"crossref","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine. 2018;379(7):633-644.","DOI":"10.1056\/NEJMoa1800256"},{"key":"7901_CR40","doi-asserted-by":"crossref","unstructured":"Sattar N, McMurray J, Bor\u00e9n J, Rawshani A, Omerovic E, Berg N, et al. Twenty years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study. Circulation. 2023;147(25):1872-1886.","DOI":"10.1161\/CIRCULATIONAHA.122.063374"},{"issue":"5","key":"7901_CR41","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.kint.2025.04.036","volume":"108","author":"R Raina","year":"2025","unstructured":"Raina R, Hu J, Chan EY, Hinton J, Mitsnefes MM. Metabolic syndrome-associated kidney disease in young adolescents and children. Kidney Int. 2025;108(5):791\u20138.","journal-title":"Kidney Int"},{"issue":"7","key":"7901_CR42","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322.","journal-title":"Nat Med"},{"issue":"12","key":"7901_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","volume":"14","author":"CJ Ferro","year":"2018","unstructured":"Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14(12):727\u201349.","journal-title":"Nat Rev Nephrol"},{"key":"7901_CR44","doi-asserted-by":"crossref","unstructured":"Suh SH, Kim SW. Dyslipidemia in patients with chronic kidney disease: an updated overview. Diabetes & Metabolism Journal. 2023;47(5):612-629.","DOI":"10.4093\/dmj.2023.0067"},{"issue":"2","key":"7901_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2020.03.006","volume":"73","author":"Z Liu","year":"2020","unstructured":"Liu Z, Zhang Y, Graham S, Wang X, Cai D, Huang M, Pique-Regi R, Dong XC, Chen YE, Willer C, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol. 2020;73(2):263\u201376.","journal-title":"J Hepatol"},{"issue":"4","key":"7901_CR46","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. lancet Diabetes Endocrinol. 2022;10(4):284\u201396.","journal-title":"lancet Diabetes Endocrinol"},{"key":"7901_CR47","doi-asserted-by":"crossref","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus \u2013 mechanisms and treatments. Nature Reviews Gastroenterology & Hepatology. 2021;18(9):599-612.","DOI":"10.1038\/s41575-021-00448-y"},{"issue":"1","key":"7901_CR48","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology (Baltimore MD). 2018;67(1):328\u201357.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"2","key":"7901_CR49","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-493.","journal-title":"Diabetes Care"},{"key":"7901_CR50","doi-asserted-by":"crossref","unstructured":"Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. International Journal of Molecular Sciences. 2016;17(4):562.","DOI":"10.3390\/ijms17040562"},{"issue":"Suppl","key":"7901_CR51","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.3350\/cmh.2022.0351","volume":"29","author":"P Konyn","year":"2023","unstructured":"Konyn P, Ahmed A, Kim D. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S43\u201357.","journal-title":"Clin Mol Hepatol"},{"key":"7901_CR52","doi-asserted-by":"crossref","unstructured":"Mellemkj\u00e6r A, Kj\u00e6r MB, Haldrup D, Gr\u00f8nb\u00e6k H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. European Journal of Internal Medicine. 2024;122:28-34.","DOI":"10.1016\/j.ejim.2023.11.012"},{"key":"7901_CR53","doi-asserted-by":"crossref","unstructured":"Ricardo AC, Madero M, Yang W, Anderson C, Menezes M, Fischer MJ, et al. Adherence to a healthy lifestyle and all-cause mortality in CKD. Clinical Journal of the American Society of Nephrology. 2013;8(4):602-609.","DOI":"10.2215\/CJN.00600112"},{"issue":"7932","key":"7901_CR54","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41586-022-05299-4","volume":"610","author":"B Chen","year":"2022","unstructured":"Chen B, Sun L, Zeng G, Shen Z, Wang K, Yin L, Xu F, Wang P, Ding Y, Nie Q, et al. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature. 2022;610(7932):562\u20138.","journal-title":"Nature"},{"issue":"1","key":"7901_CR55","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-023-02793-y","volume":"21","author":"F Petermann-Rocha","year":"2023","unstructured":"Petermann-Rocha F, Wirth MD, Boonpor J, Parra-Soto S, Zhou Z, Mathers JC, Livingstone K, Forrest E, Pell JP, Ho FK, et al. Associations between an inflammatory diet index and severe non-alcoholic fatty liver disease: a prospective study of 171,544 UK Biobank participants. BMC Med. 2023;21(1):123.","journal-title":"BMC Med"},{"issue":"1","key":"7901_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41387-024-00300-7","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang J, Jiang Y, Jin L, Qian C, Zuo W, Lin J, Xie L, Jin B, Zhao Y, Huang L, et al. Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease. Nutr diabetes. 2024;14(1):41.","journal-title":"Nutr diabetes"},{"key":"7901_CR57","doi-asserted-by":"crossref","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. Journal of Hepatology. 2017;67(4):829-846.","DOI":"10.1016\/j.jhep.2017.05.016"},{"key":"7901_CR58","doi-asserted-by":"crossref","unstructured":"Ahmed S, Alam W, Aschner M, Alsharif KF, Albrakati A, Saso L, et al. Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy. Biomedicine & Pharmacotherapy. 2022;155:113797.","DOI":"10.1016\/j.biopha.2022.113797"},{"issue":"2","key":"7901_CR59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41581-023-00775-0","volume":"20","author":"S Kishi","year":"2024","unstructured":"Kishi S, Nagasu H, Kidokoro K, Kashihara N. Oxidative stress and the role of redox signalling in chronic kidney disease. Nat Rev Nephrol. 2024;20(2):101\u201319.","journal-title":"Nat Rev Nephrol"},{"key":"7901_CR60","doi-asserted-by":"crossref","unstructured":"Allameh A, Niayesh-Mehr R, Aliarab A, Sebastiani G, Pantopoulos K. Oxidative stress in liver pathophysiology and disease. Antioxidants. 2023;12(9).","DOI":"10.3390\/antiox12091653"},{"key":"7901_CR61","doi-asserted-by":"publisher","first-page":"101143","DOI":"10.1016\/j.molmet.2020.101143","volume":"50","author":"KK Bence","year":"2021","unstructured":"Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol metabolism. 2021;50:101143.","journal-title":"Mol metabolism"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07901-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07901-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07901-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:41:44Z","timestamp":1775817704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07901-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7901"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07901-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee. All participants gave written informed consent before enrolment in the study, which was conducted in accord with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"495"}}